Valeo Pharma Inc., a Canadian pharmaceutical company, has appointed Frederic Fasano to the newly created position of President and Chief Operating Officer, to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors.
 
Mr. Fasano is a seasoned pharma executive with over 25 years of experience in managing strategic affiliates in Canada, Europe, Latin America. Prior to joining Valeo, Frederic served as President and CEO of Servier Canada, where he led the portfolio diversification strategy, including multiple in-licensing deals, while strengthening the team capabilities in order to maximize growth. Mr. Fasano held various executive positions in Italy, France and Latin America and sat on the Board of Directors of ILKOS Therapeutics. He also served as Chairman of the Board of Innovative Medicines Canada.
 
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus,” said Steve Saviuk,  CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”